Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Patritumab (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Inc
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 13 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Oct 2013 New trial record